[妊娠期间使用氨氯地平的立场声明。]阿根廷高血压学会妇女高血压工作组]。

IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Hipertension y Riesgo Vascular Pub Date : 2025-04-01 DOI:10.1016/j.hipert.2024.11.004

A.M. Ghelfi , G. Miranda , L.S. Voto , M.A. Del Sueldo , J.M. Zilberman , R. Mondino , M.P. Pérez , P.G. Irusta , L. Meccia , E. Martínez Marissi , M. Laura Baiche , F. Waisman , M. BaronI , M. Victoria FerrettI , J.P. Morán , A. Corrales Barboza , A.M. Delucchi , P.D. Rodríguez , N.F. Renna

{"title":"[妊娠期间使用氨氯地平的立场声明。]阿根廷高血压学会妇女高血压工作组]。","authors":"A.M. Ghelfi , G. Miranda , L.S. Voto , M.A. Del Sueldo , J.M. Zilberman , R. Mondino , M.P. Pérez , P.G. Irusta , L. Meccia , E. Martínez Marissi , M. Laura Baiche , F. Waisman , M. BaronI , M. Victoria FerrettI , J.P. Morán , A. Corrales Barboza , A.M. Delucchi , P.D. Rodríguez , N.F. Renna","doi":"10.1016/j.hipert.2024.11.004","DOIUrl":null,"url":null,"abstract":"<div><div>Pharmacological management of HDP includes agents supported by extensive evidence ensuring their safety for use. Among those traditionally described in the literature are: alpha-methyldopa, labetalol, and sustained-release nifedipine (NIF-RETARD). These drugs, in addition to being compatible with pregnancy, present additional eligibility criteria.</div><div>The discontinuation of NIF-RETARD has resulted in the off-label use of other dihydropyridine calcium cannel blockers with lower levels of evidence in pregnancy, such as amlodipine.</div><div>The Working Group Hypertension in Women of the Argentine Society of Hypertension has proposed to develop a document that precisely and thoroughly addresses the concerns related to the use of amlodipine in pregnancy, providing responses based on the currently available scientific evidence.</div></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"42 2","pages":"Pages 102-107"},"PeriodicalIF":1.3000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Position statement on the use of amlodipine during pregnancy. Working Group on Hypertension in Women, Argentine Society of Hypertension\",\"authors\":\"A.M. Ghelfi , G. Miranda , L.S. Voto , M.A. Del Sueldo , J.M. Zilberman , R. Mondino , M.P. Pérez , P.G. Irusta , L. Meccia , E. Martínez Marissi , M. Laura Baiche , F. Waisman , M. BaronI , M. Victoria FerrettI , J.P. Morán , A. Corrales Barboza , A.M. Delucchi , P.D. Rodríguez , N.F. Renna\",\"doi\":\"10.1016/j.hipert.2024.11.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Pharmacological management of HDP includes agents supported by extensive evidence ensuring their safety for use. Among those traditionally described in the literature are: alpha-methyldopa, labetalol, and sustained-release nifedipine (NIF-RETARD). These drugs, in addition to being compatible with pregnancy, present additional eligibility criteria.</div><div>The discontinuation of NIF-RETARD has resulted in the off-label use of other dihydropyridine calcium cannel blockers with lower levels of evidence in pregnancy, such as amlodipine.</div><div>The Working Group Hypertension in Women of the Argentine Society of Hypertension has proposed to develop a document that precisely and thoroughly addresses the concerns related to the use of amlodipine in pregnancy, providing responses based on the currently available scientific evidence.</div></div>\",\"PeriodicalId\":39403,\"journal\":{\"name\":\"Hipertension y Riesgo Vascular\",\"volume\":\"42 2\",\"pages\":\"Pages 102-107\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hipertension y Riesgo Vascular\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1889183724001168\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hipertension y Riesgo Vascular","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1889183724001168","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

HDP的药理学管理包括有大量证据支持的药物，以确保其使用安全。传统文献中描述的有：甲多巴、拉贝他洛尔和缓释硝苯地平（NIF-RETARD）。这些药物除了与妊娠相容外，还提出了额外的资格标准。NIF-RETARD的停药导致了其他双氢吡啶钙通道阻滞剂的超说明书使用，如氨氯地平，证据表明其在妊娠期的使用水平较低。阿根廷高血压学会妇女高血压工作组建议制定一份文件，精确和彻底地解决与妊娠期间使用氨氯地平有关的问题，根据现有的科学证据提供答复。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Position statement on the use of amlodipine during pregnancy. Working Group on Hypertension in Women, Argentine Society of Hypertension

Pharmacological management of HDP includes agents supported by extensive evidence ensuring their safety for use. Among those traditionally described in the literature are: alpha-methyldopa, labetalol, and sustained-release nifedipine (NIF-RETARD). These drugs, in addition to being compatible with pregnancy, present additional eligibility criteria.

The discontinuation of NIF-RETARD has resulted in the off-label use of other dihydropyridine calcium cannel blockers with lower levels of evidence in pregnancy, such as amlodipine.

The Working Group Hypertension in Women of the Argentine Society of Hypertension has proposed to develop a document that precisely and thoroughly addresses the concerns related to the use of amlodipine in pregnancy, providing responses based on the currently available scientific evidence.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Hipertension y Riesgo Vascular Medicine-Internal Medicine

CiteScore

1.70

自引率

16.70%

发文量

审稿时长

39 days

期刊介绍： La mejor publicación para mantenerse al día en los avances de la lucha contra esta patología. Incluye artículos de Investigación, Originales, Revisiones, Casos clínicos, Aplicación práctica y Resúmenes comentados a la bibliografía internacional. Además, es la Publicación Oficial de la Sociedad española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial.